Cyto-Facto Inc. provides services for manufacturing, development, and quality control testing of gene and cell preparations. We will contribute to the realization of a healthy society by providing the latest gene and cell products in a timely and reliable manner to patients in need of gene and cell therapy.
Location: Japan, Chuo
Employees: 51-200
Investors 1
| Date | Name | Website |
| - | Kobe Unive... | kuc.vc |
Mentions in press and media 3
| Date | Title | Description |
| 22.04.2024 | D3LLC makes follow-on investment in Series A round (1.18 billion yen) in Gene & Cell Therapy CDMO Site-Fact | D3 LLC D3LLC makes follow-on investment in Series A round (1.18 billion yen) in Gene & Cell Therapy CDMO Site-Fact Through a fund managed by D3LLC, we made our second follow-on investment following the spin-out investment from Kobe City... |
| 22.04.2024 | Cyto-Fact Co., Ltd. Cyto-Fact, a CMO/CDMO specializing in gene and cell preparations, raised 1.18 billion yen through Series A third-party allotment. | Site-Fact Co., Ltd. Cyto-Fact, a CMO/CDMO specializing in gene and cell preparations, raised 1.18 billion yen through Series A third-party allotment. …… [Image 1: https://prtimes.jp/i/125654/4/resize/d125654-4-8d378ba55c77887153a1-0.jpg&... |
| - | Cyto-Facto | “Cyto-Facto Inc. provides services for manufacturing, development, and quality control testing of gene and cell preparations. We will contribute to the realization of a healthy society by providing the latest gene and cell products in a tim... |